Dear Colleagues:
Welcome to the September issue of Innovations in Clinical Neuroscience. In this issue, we are pleased to present three interesting case reports. In the first report titled, “Omeprazole-induced Blood Dyscrasia in a Clozapine-treated Patient” by Philipps et al, the authors describe a case of probable omeprazole-induced blood dyscrasia in a clozapine-treated patient. With proton pump inhibitors being one of the world’s most widely used therapeutic class of drugs, psychiatrists should keep this rare but dangerous risk in mind for their patients who take clozapine.
Next, we present a report titled, “An OCD Patient Presenting with a Cerebellum Venous Variant in a Family with a Strong Schizophrenia Loading: A Case Report” by Palma et al. The authors report the case of a 32-year-old woman with obsessive-compulsive disorder and a cerebellum development variant in a family with a strong schizophrenia loading. This case emphasizes the probable role of the cerebellum in the pathophysiology of both obsessive-compulsive disorder and schizophrenia, and reconsiders the existence of a so-called schizo-obsessive subtype of schizophrenia.
Our third and final case report is titled, “A Risperidone-Induced Prolactinoma Resolved when a Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report” by Arcari et al. Here, the authors present a case of a woman with schizoaffective disorder who developed endocrine abnormalities, including an increase in serum prolactin level (sPrl), due to a drug-induced benign pituitary tumor (prolactinoma) after being switch from thioridazine to risperidone. The prolactinoma completely resolved with a switch to ziprasidone.
We close the issue with two of our regular columns. In “The Interface,” Sansone and Sansone explore employment outcomes in patients with borderline personality disorder. And in this month’s “Risk Management,” Ali examines the ADA requirement of providing interpreters for patients with hearing disabilities.
We hope you enjoy the issue and as always invite your comments.
Sincerely,
Amir Kalali, MD
Editor, Innovations in Clinical Neuroscience
